Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 170

1.

An immunological biomarker to predict MTX response in early RA.

Ponchel F, Goëb V, Parmar R, El-Sherbiny Y, Boissinot M, El Jawhari J, Burska A, Vital EM, Harrison S, Conaghan PG, Hensor E, Emery P.

Ann Rheum Dis. 2014 Nov;73(11):2047-53. doi: 10.1136/annrheumdis-2013-203566. Epub 2013 Aug 29.

PMID:
23989988
2.

Clinical and radiological dissociation of anti-TNF plus methotrexate treatment in early rheumatoid arthritis in routine care: results from the ABRAB study.

Juhász P, Mester A, Biró AJ, Héjj G, Poór G.

BMC Musculoskelet Disord. 2014 Jul 24;15:251. doi: 10.1186/1471-2474-15-251.

3.

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.

Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Barré E, Karyekar CS, Wong DA, Huizinga TW.

Ann Rheum Dis. 2015 Jan;74(1):19-26. doi: 10.1136/annrheumdis-2014-206106. Epub 2014 Nov 3.

4.

The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.

Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, van der Heijde D, Miyasaka N, Koike T.

Ann Rheum Dis. 2016 Jan;75(1):75-83. doi: 10.1136/annrheumdis-2015-207511. Epub 2015 Jul 2.

5.

Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?

Saleem B, Keen H, Goeb V, Parmar R, Nizam S, Hensor EM, Churchman SM, Quinn M, Wakefield R, Conaghan PG, Ponchel F, Emery P.

Ann Rheum Dis. 2010 Sep;69(9):1636-42. doi: 10.1136/ard.2009.117341. Epub 2010 Apr 26. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1520.

PMID:
20421345
6.

Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.

Wells AF, Westhovens R, Reed DM, Fanti L, Becker JC, Covucci A, Keystone EC.

J Rheumatol. 2011 Nov;38(11):2362-8. doi: 10.3899/jrheum.110054. Epub 2011 Sep 1.

7.

Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study).

van Aken J, Heimans L, Gillet-van Dongen H, Visser K, Ronday HK, Speyer I, Peeters AJ, Huizinga TW, Allaart CF.

Ann Rheum Dis. 2014 Feb;73(2):396-400. doi: 10.1136/annrheumdis-2012-202967. Epub 2013 Jan 19.

PMID:
23334213
8.

The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study.

Szalay B, Vásárhelyi B, Cseh A, Tulassay T, Deák M, Kovács L, Balog A.

Clin Rheumatol. 2014 Feb;33(2):175-85. doi: 10.1007/s10067-013-2352-x. Epub 2013 Aug 11.

PMID:
23934385
9.

Induction therapy with combination TNF inhibitor and methotrexate in early rheumatoid arthritis.

Hwang YG, Moreland LW.

Curr Rheumatol Rep. 2014 May;16(5):417. doi: 10.1007/s11926-014-0417-8. Review.

PMID:
24619653
10.

A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial.

Nam JL, Villeneuve E, Hensor EM, Wakefield RJ, Conaghan PG, Green MJ, Gough A, Quinn M, Reece R, Cox SR, Buch MH, van der Heijde DM, Emery P.

Ann Rheum Dis. 2014 Jun;73(6):1027-36. doi: 10.1136/annrheumdis-2013-204882. Epub 2014 Mar 11.

PMID:
24618266
11.

Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis.

Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU.

Arthritis Rheum. 2009 Aug;60(8):2272-83. doi: 10.1002/art.24638. Erratum in: Arthritis Rheum. 2010 Oct;62(10):3005.

12.
13.

Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.

Barrera P, van der Maas A, van Ede AE, Kiemeney BA, Laan RF, van de Putte LB, van Riel PL.

Rheumatology (Oxford). 2002 Apr;41(4):430-9.

14.
15.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

16.

Anti-TNF-α therapy improves Treg and suppresses Teff in patients with rheumatoid arthritis.

Huang Z, Yang B, Shi Y, Cai B, Li Y, Feng W, Fu Y, Luo L, Wang L.

Cell Immunol. 2012 Sep;279(1):25-9. doi: 10.1016/j.cellimm.2012.09.001. Epub 2012 Sep 19.

PMID:
23059810
17.

Is it possible to withdraw biologics from therapy in rheumatoid arthritis?

Tanaka Y, Hirata S.

Clin Ther. 2013 Dec;35(12):2028-35. doi: 10.1016/j.clinthera.2013.10.008. Epub 2013 Nov 28. Review.

PMID:
24290736
18.

Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents.

Picchianti Diamanti A, Rosado MM, Scarsella M, Germano V, Giorda E, Cascioli S, Laganà B, D'Amelio R, Carsetti R.

Clin Exp Immunol. 2014 Sep;177(3):630-40. doi: 10.1111/cei.12367.

19.

Adalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.

Takeuchi T, Yamanaka H, Ishiguro N, Miyasaka N, Mukai M, Matsubara T, Uchida S, Akama H, Kupper H, Arora V, Tanaka Y.

Ann Rheum Dis. 2014 Mar;73(3):536-43. doi: 10.1136/annrheumdis-2012-202433. Epub 2013 Jan 11.

20.

Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis.

Chara L, Sánchez-Atrio A, Pérez A, Cuende E, Albarrán F, Turrión A, Chevarria J, Sánchez MA, Monserrat J, de la Hera A, Prieto A, Sanz I, Diaz D, Alvarez-Mon M.

Arthritis Res Ther. 2012 Jul 27;14(4):R175. doi: 10.1186/ar3928.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk